1 / 60

Pneumococcal Disease in Children: P.S. It Matters

Pneumococcal Disease in Children: P.S. It Matters. Learning Objectives. Describe the current burden of pneumococcal disease since the introduction of pneumococcal conjugate vaccines Discuss the current recommended immunization schedule in infants and children to prevent pneumococcal disease

wilson
Télécharger la présentation

Pneumococcal Disease in Children: P.S. It Matters

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Pneumococcal Disease in Children: P.S. It Matters

  2. Learning Objectives • Describe the current burden of pneumococcal disease since the introduction of pneumococcal conjugate vaccines • Discuss the current recommended immunization schedule in infants and children to prevent pneumococcal disease • Review and implement strategies for improving immunization rates within one’s clinical practice, including being able to answer frequently encountered questions that involve safety, efficacy, and possible misinformation

  3. Streptococcus pneumoniae • A leading bacterial cause of serious illness among children and adults worldwide • Gram-positive bacteria • Polysaccharide capsule important pathogenic factor; prevents phagocytosis • Over 90 distinct capsular types identified • Protection is serotype specific; some cross protection within serogroups Lynch J, Zhanel G. Semin Respir Crit Care Med. 2009;30(2):189-209.

  4. Pneumococcal Disease • Influenza and pneumococcal disease are the most common causes of vaccine-preventable disease and death in the US • Major pneumococcal clinical syndromes include • Pneumonia • Bacteremia • Meningitis • Invasive pneumococcal disease (IPD): isolation of S. pneumoniae from a normally sterile site (blood, CSF, pleural, pericardial, peritoneal, bone or joint fluid) • Pneumococcal diseases encompass invasive and non-invasive syndromes Adapted from CDC. http://www.cdc.gov/vaccines/pubs/pinkbook/pneumo.html. Accessed Nov 2011.

  5. Invasive Pneumococcal DiseaseClinical SyndromesActive Bacterial Core Surveillance USA 2006–2007 Pilishvili T, et al. J Infect Dis. 2010;201:32-41.

  6. S. Pneumoniae ABCs Data USA: 2009Invasive Pneumococcal Disease (Inpatient and Outpatient) CDC ABC Surveillance report. http://www.cdc.gov/abcs/reports-findings/survreports/spneu09.html. Accessed Nov 2011.

  7. S. Pneumoniae ABCs Data–2009All Age Groups Meningitis 4.8% Bacteremia without Focus 19.2% Not Categorized 5.6% Pneumonia with Bacteremia 70.4% Based on a total of 4,166 IPD cases CDC ABC Surveillance report. http://www.cdc.gov/abcs/reports-findings/survreports/spneu09.html. Accessed Nov 2011.

  8. S. pneumoniae Carriage and Infection • Nasopharyngeal carriage of S. pneumoniae necessary for transmission of bacteria and invasive disease • Person-to-person contact; respiratory droplets • Autoinoculation • Seasonal patterns • S. pneumoniae can be present in the nasopharynx commensally and not cause disease Pneumococcal disease. http://www.cdc.gov/vaccines/pubs/pinkbook/pneumo.html. Accessed Nov 2011.

  9. Pneumococcal Disease in Children • Bacteremia without known site of infection most common clinical presentation • Bacteremic pneumonia accounts for 12–16% of IPD among children 2 years and younger • S. pneumoniae leading cause of bacterial meningitis among children 2 months to 10 years • Group B streptococcus leading cause of meningitis in children < 2 months • Common cause of acute otitis media Pneumococcal disease. http://www.cdc.gov/vaccines/pubs/pinkbook/pneumo.html. Accessed Nov 2011. Thigpen M, et al. N Engl J Med. 2011;364:2016-2025.

  10. Pneumococcal Acute Otitis Media (AOM) • Most common reason for physician office visits among pre-school aged children in the US • 83% of children experience ≥ 1 episode of AOM before 36 months of age • S. pneumoniae most common bacterial cause of AOM (30–50% of episodes) • AOM most common reason for antibiotic prescriptions among US children Zhou F, et al. Pediatrics. 2008;121:253-260.

  11. Annual Global Pneumococcal Deaths in Children#1 Vaccine-Preventable Cause of Death in Children < 5 Years Worldwide Deaths per 100,000 children < 5 years O’Brien K, et al. Lancet. 2009;374:893-902.

  12. Risk Factors for Pneumococcal Diseases or Complications • Immunocompetent children • Chronic heart disease • Chronic lung disease • Diabetes mellitus • Cerebrospinal fluid leaks • Cochlear implant • Children with functional or anatomic asplenia • Sickle cell disease and other hemoglobinopathies • Congenital or acquired asplenia, or splenic dysfunction • Children with immunocompromising conditions • HIV infection • Chronic renal failure and nephrotic syndrome • Diseases associated with treatment with immunosuppressive drugs or radiation therapy; or solid organ transplantation • Congenital immunodeficiency CDC. MMWR Recomm Rep. 2010;59(RR-11):1-18.

  13. Vaccines for Invasive Pneumococcal Disease (before PCV-13) Pneumococcal disease. http://www.cdc.gov/vaccines/pubs/pinkbook/pneumo.html. Accessed Nov 2011. Lynch J, Zhanel G. Sem Respir Crit Care Med. 2009;30(2):189-209.

  14. Changes in Overall Invasive Pneumococcal Disease, 1998–2007 PCV7 introduced Age Group 2007 vs baseline* (years) (% reduction) 120 < 5 76 100 5–17 43 40 18–49 50–64 18 80 Cases/100,000 population ≥ 65 37 60 40 20 0 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 Year *Baseline is 1998-1999 Pilishvili T, et al. J Infect Dis. 2010;201:32-41.

  15. Direct Effect of Vaccination: Invasive Pneumococcal Disease Among Children < 5 Years, 1998/99–2007 PCV7 introduced 90 80 Serotype group 70 PCV7 type Non-PCV7 type 60 19A 50 Cases/100,000 population 40 30 20 10 0 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 Year Pilishvili T, et al. J Infect Dis. 2010;201:32-41.

  16. Invasive Pneumococcal Disease (IPD) Mortalityin Children < 2 Years; Vital Records USA 1.0 0.9 0.8 0.7 0.6 Mortality Rate per 100,000 Population 0.5 0.4 0.3 Overall IPD Mortality Pneumococcal Meningitis Mortality Pneumococcal Septicemia Mortality 0.2 0.1 0 1995 1996 1997 1998 1999 2000 2001 Redelings MD, et al. Arch Pediatr Adolesc Med. 2005;159:195-196.

  17. Herd Immunity: Invasive Pneumococcal Disease Among Adults ≥ 65 Years, 1998/99–2007 PCV7 introduced 40 35 *92% reduction in PCV7 serotypes, 2007 vs baseline 30 25 Serotype group Cases/100,000 Population 20 PCV7 type Non-PCV7 type 15 19A 10 5 * 0 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 Year *Baseline is 1998-1999 Pilishvili T, et al. J Infect Dis. 2010;201:32-41.

  18. Herd Immunity: Invasive Pneumococcal Disease in Infants 0 to 90 days,1997–2004 Poehling K, et al. JAMA. 2006;295:1668-1674.

  19. * * * * * Rates of Invasive Pneumococcal DiseaseMetropolitan Atlanta, Georgia 18 16 14 12 10 Cases per 100,000 Persons 8 6 4 2 0 Bacteremia Meningitis Pneumonia Bacteremia Meningitis Pneumonia Children < 18 years Adults ≥ 18 years 2000/01 2001/02 2002/03 2003/04 *Clinical syndromes with significant trends over time 2000/2001 to 2003/2004; P≤ 0.05 Albrich WC, et al. Clin Infect Dis. 2007;44:1569-1576.

  20. ABCIncidence of Pneumococcal Meningitis by PCV7 ST Group Over Time: All Ages 1.2 Non-PCV7 STs PCV7-related STs 1.0 PCV7 STs 0.8 Meningitis Cases/100,000 Persons 0.6 0.4 0.2 0.0 1998–1999 2000–2001 2002–2003 2004–2005 Hsu HE, et al. N Engl J Med. 2009;360:244-256.

  21. ABCIncidence of Pneumococcal Meningitis by PCV7 ST Group Over Time: < 2 Years Hsu HE, et al. N Engl J Med. 2009;360:244-256.

  22. PCV Efficacious in Reducing Radiologically Confirmed Pneumonia in Children Navajo, USA (Rural) American Indians PCV-7 Cluster randomized VE: -2%; P > 0.05 The Gambia PCV-9 DBRCT VE: 37%; 95%CI 27, 45% Northern California, USA PCV-7 DBRCT VE: 30%; 95%CI 11, 46% Philippines (Rural) PCV-11 DBRCT VE: 22.9; 95%CI -1, 41 South Africa (Urban) PCV-9 DBRCT HIV-infected children VE: 9% (95%CI -15 to 27) HIV non-infected children VE: 25% (95%CI 4 to 41) Black S, et al. Pediatr Infect Dis J. 2001;20:1105-1107. Hansen J, et al. Pediatr Infect Dis J. 2006;25:779-781. Klugman KP, et al. N Engl J Med. 2003;349:1341-1348. Cutts F, et al. Lancet. 2005;365:1139-1146. Lucero MG, et al. Pediatr Infect Dis J. 2009;28:455-462. VE: vaccine effectiveness

  23. Efficacy of PCV in Children < 2 Years • 11 publications of 6 randomized controlled trials • N = 57,015 children received PCV; N = 56,029 received placebo or another vaccine • Vaccine-serotype IPD; RR = 0.20 (0.10-0.42); P < 0.0001 • All serotypes IPD; RR = 0.42 (0.25-0.71); P = 0.001 • WHO X-ray defined pneumonia; RR = 0.73 (0.64-0.85); P < 0.0001 • Clinical pneumonia; RR = 0.94 (0.91-0.98); P = 0.0006 • All-cause mortality; RR = 0.91 (0.81-1.01); P = 0.07 Lucero M, et al. Cochrane Database Syst Rev. 2009;4:CD004977.

  24. National Estimated Changes in Rates of Pneumonia Hospitalizations Post PCV7 All-cause Pneumonia; Nationwide Inpatient Sample Change comparing 2004 data with pre-PCV7 years after trend adjustment Grijalva C, et al. Lancet. 2007;369:1179-1186. Grijalva C, Griffin M. Expert Rev Vaccines. 2008;7:83-95. *Statistically significant decline

  25. PCV7 and Community Acquired PneumoniaRetrospective Cohort of Children and Adults–Washington State HMO Nelson J, et al. Vaccine. 2008;26:4947-4954.

  26. Estimated PCV7-Associated Reductions in US Burden of Hospitalizations, 2000–2006 SimonsenL, et al.mBio. 2011;2:e00309-e00310.

  27. Efficacy of PCV7 for Acute Otitis Media (AOM)Kaiser Permanente Randomized Double-Blind Trial *number of episodes in 6months/number of episodes in 1 year N = 37,868 infants; vaccine at 2, 4, 6, and 12 to 15 months of age; meningococcal vaccine as control Black S, et al. Pediatr Infect Dis. 2000;19:187-195.

  28. Efficacy of PCV7 for Acute Otitis Media (AOM)Finnish Otitis Media Vaccine Trial N = 1662 infants; vaccine at 2, 4, 6, and 12 months of age; Hepatitis B vaccine as control Eskola J, et al. N Engl J Med. 2001;344:403-409.

  29. Ambulatory Visits for Acute Otitis Media and Antibiotic Prescriptions1997–2004 MarketScan Databases 2500 2000 1500 Rate (per 1000 person-years) 1000 Ambulatory visits for AOM 500 Non-AOM ARI visits Antibiotic prescriptions for AOM visits Antibiotic prescriptions for non-AOM ARI visits 0 1997 1998 1999 2000 2001 2002 2003 2004 Year AOM: acute otitis media; ARI: acute respiratory infection Zhou F, et al. Pediatrics. 2008;121:253-260.

  30. Impact of PCV7 on Otitis Media Reduction in Antibiotic Use Fireman B, et al. Pediatr Infect Dis J. 2003;22:10-16.

  31. Penicillin Resistance in PCV7 Serotypes Northern California Kaiser Permanente (All ages) PCV7 Introduced Black S, et al. Pediatr Infect Dis J. 2004;23:485-489.

  32. Invasive Pneumococcal Disease in Children < 2 Years Active Bacterial Core Surveillance (ABCs) Data Kyaw M, et al. N Engl J Med. 2006;354:1455-1463.

  33. Invasive Pneumococcal Disease Penicillin Non-susceptible (≥ 2 years) ABCs Data Kyaw M, et al. N Engl J Med. 2006;354:1455-1463.

  34. Effect of Introduction of PCV-7 on Drug-Resistant S. pneumoniae Kyaw M, et al. N Engl J Med. 2006;354:1455-1463.

  35. Invasive Pneumococcal Disease Serotype 19A Moore M, et al. J Infect Dis. 2008;197:1016-1027.

  36. Trends in Antibiotic Resistance: Serotype 19A Children < 5 Years Moore M, et al. J Infect Dis. 2008;197:1016-1027.

  37. IPD and S. pneumoniae Serotypes Children < 5 years Adults > 50 years White bars: penicillin susceptible; gray bars: penicillin intermediate; black bars: penicillin resistant Moore M, et al. J Infect Dis. 2008;197:1016-1027.

  38. Outpatient Antibiotic Prescribing and S. pneumoniae Serotype 19A IPD Isolates Hicks L, et al. Clin Infect Dis. 2011;53:631-639.

  39. Children With New Acquisition of Serotype 19A After Finishing Primary Series PCV7 van Gils E, et al. JAMA. 2010;304:1099-1106.

  40. Antibiotic Use and PCV7 in Children with AOMFrench Prospective Study Antibiotics (+): Antibiotic use within the last 3 months Cohen R, et al. Pediatr Infect Dis J. 2006;25:1001-1007.

  41. Distribution of Penicillin Non-Susceptible Invasive Pneumococcal Isolates–ABCs 2007 (all age groups) Serotype 6A (n = 38) Serotypes 15A, 35B, 23A, 6C (n = 287) 11%, 8%, 8%, 5% Total = 32% Serotype 19A (n = 478) Others (n = 32) [13 serotypes, 2 isolates nontypeable] PCV7 Serotypes (n = 61) 25.6% of 3,511 total isolates were penicillin non-susceptible Gertz R, et al. J Infect Dis. 2010;201:770-775.

  42. Expanded Serotype Coverage with PCV13

  43. 13-Valent Pneumococcal Conjugate Vaccine (PCV13) • Licensed by FDA on February 24, 2010 • Serotypes in PCV13 • PCV7 types: 4, 6B, 9V, 14, 18C, 19F, 23F • Additional serotypes: 1, 3, 5, 6A, 7F, 19A • Approved for use in children 6 weeks through 5 years (before the 6th birthday) • 4-dose series at ages 2, 4, 6, and 12-15 months • Indications • Prevention of invasive pneumococcal disease (IPD) caused by the 13 vaccine serotypes • Prevention of otitis media caused by PCV7 serotypes CDC. MMWR Morb Mortal Wkly Rep. 2010;59(9):258-261.

  44. 2012 Child Immunization Schedule ACIP Schedules. http://www.cdc.gov/vaccines/recs/schedules/default.htm. Accessed Feb 2012.

  45. PCV13 Recommended Schedules for Children < 24 Months CDC. MMWR Recomm Rep. 2010;59(RR-11):1-18.

  46. Transition from PCV7 to PCV13 Accordingto Number of Doses Previously Received *No additional PCV13 doses are indicated for children 12-23 months who received 2 or 3 doses or PCV7 before age 12 months and at least 1 dose of PCV13 at age ≥ 12months **For children with underlying medical conditions, a supplemental PCV13 dose is recommended through 71 months of age CDC. MMWR Morb Mortal Wkly Rep. 2010;59(9):258-261.

  47. PCV13 Recommended Schedules for Children ≥ 24 Months *For children who have underlying medical conditions, a supplemental PCV13 dose is recommended through 71 months of age CDC. MMWR Recomm Rep. 2010;59(RR-11):1-18.

  48. Invasive Pneumococcal Disease Caused by Serotype 19A: A Preventable Death? • June 2011, a 2-year-old girl in California died from IPD caused by serotype 19A • Serotype 19A is included in PCV13, but not PCV7 • The child had received 3 doses of PCV7, but had NOT received PCV13 • California Dept. of Public Health identified an additional 30 PCV-13 eligible children who had developed nonfatal IPD caused by serotypes not included in PCV7 CDC. MMWR Wkly Rep. 2011;60:1477-1481.

  49. Coverage with PCV13, Immunization Information System (IIS) Sentinel Sites, US March 12, 2010–June 30, 2011 • During 2010 and 2011, evaluated PCV13-type IPD cases and vaccine coverage in children ≤ 59 months • Among ~850,000 children aged 12 through 59 months with a complete PCV7 series as of March 2010, 37% received the supplemental dose as of June 30, 2011 • CDC PCV13 Vaccine Effectiveness Evaluation • 68% of cases of IPD due to the new serotypes in PCV13 were among vaccine-eligible children 24–59 months *On or after March 12, 2010; unweighted average across sites CDC. MMWR Wkly Rep. 2011;60:1477-1481.

  50. 2010 CDC ABC Data–IPD Rates All Serotypes and PCV13 Serotypes Children < 2 Years Moore M, et al. 51st Interscience Conference on Antimicrobial Agents and Chemotherapy;Chicago, IL 2011: G1-538.

More Related